Test your knowledge of treatment of early relapsed multiple myeloma with iberdomide, daratumumab, and dexamethasone

What is the most common side effect with iberdomide in combination with daratumumab and dex (IberDd)?
CRS
Anemia
Neutropenia
Venous thromboembolism
Patients should receive a CELMoD after CAR-T due to concerns of exhausting T cells.
True
False
The phase III EXCALIBER-RRMM trial demonstrated MRD rates of ___ in the IberDd arm.
76.1%
41.1%
20.7%
88.9%
0
{"name":"Test your knowledge of treatment of early relapsed multiple myeloma with iberdomide, daratumumab, and dexamethasone", "url":"https://www.poll-maker.com/QGIQKXA5S","txt":"What is the most common side effect with iberdomide in combination with daratumumab and dex (IberDd)?, Patients should receive a CELMoD after CAR-T due to concerns of exhausting T cells., The phase III EXCALIBER-RRMM trial demonstrated MRD rates of ___ in the IberDd arm.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker